Every Form 4 that Compugen Ltd (CGEN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGEN filings page.
COMPUGEN LTD SVP, Business Development Zurit Levine reported equity awards. The insider received 18000.0000 restricted stock units and 24000.0000 share options at an exercise price of 2.2600 per share, each vesting 25% on September 30, 2027 and the remainder in 12 equal quarterly installments, contingent on continued service, resulting in 47375.0000 ordinary shares held directly.
Compugen Ltd granted Chief Financial Officer David Silberman 19,500 restricted stock units and 26,000 share options on July 29, 2026. The options have an exercise price of 2.2600 and expire on July 29, 2036. Both awards vest 25% on September 30, 2027, with the remainder in 12 equal quarterly installments, subject to continued service. Following the RSU grant, Silberman directly holds 55,000 ordinary shares and 26,000 options.
Compugen Ltd President and CEO Ophir Eran received a grant of 200000.0000 share options for ordinary shares on 2026-07-29. The options carry a $2.2600 exercise price and expire on 2036-07-29. They vest 25% on September 30, 2027, then in 12 equal quarterly installments, subject to continued service.
Compugen Ltd reported that director Anat Cohen-Dayag received a grant of 100,000 share options to purchase Ordinary Shares at an exercise price of $2.2600 per share. The option expires on 2036-07-29 and vests 25% on September 30, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued service. Following this award, the reported derivative holdings from this grant total 100,000 options.
Compugen director Eran Perry reported two equity awards dated 2026-07-29: a grant of 10,000 share options to buy ordinary shares at an exercise price of $2.2600 expiring 2036-07-29, and an award of 7,500 restricted stock units. Both grants vest 25% on October 1, 2027, with the balance vesting in 12 equal quarterly installments, subject to continued service. Following these awards, Perry directly holds 17,500 ordinary shares and options for 10,000 shares.
Compugen Ltd granted Chief Operating Officer Pierre Ferre 70,000 share options over ordinary shares at an exercise price of $4.00 per share, expiring on July 29, 2036. The option vests 25% on September 30, 2027, with the remainder vesting in 12 equal quarterly installments, subject to his continued service.
Compugen Ltd (CGEN) reported equity awards to executive Kredo Russo Sharon, SVP, Research & Discovery. On July 29, 2026, she received 18,000 restricted stock units representing ordinary shares and options for 24,000 ordinary shares at a $2.26 exercise price, expiring July 29, 2036. Both awards vest 25% on September 30, 2027, with the balance vesting in 12 equal quarterly installments, subject to continued service. Following the RSU grant, 37,500 ordinary shares are reported as directly owned.
Livnat Savitzky Kinneret reported acquisition or exercise transactions in this Form 4 filing.
Compugen director Livnat Savitzky Kinneret received equity awards on July 29, 2026, including options to purchase 10,000 Ordinary Shares at $2.26 per share expiring July 29, 2036, and 7,500 restricted stock units. Both awards vest 25% on October 1, 2027, with the remainder in 12 equal quarterly installments, subject to continued service. Following the RSU grant, her direct holdings of Ordinary Shares are reported as 20,850, and she also holds the 10,000-share option grant.
Compugen Ltd. director Mathias Hukkelhoven reported equity awards dated July 29, 2026. He received options for 10,000 Ordinary Shares at an exercise price of $2.2600, expiring July 29, 2036, and an RSU award for 7,500 shares. Both awards vest 25% on October 1, 2027, with the remainder in 12 equal quarterly installments, subject to continued service. Following the RSU grant, he directly holds 17,500 Ordinary Shares.
COMPUGEN LTD director Halevy Gilead received new equity awards on July 29, 2026. The grants consist of 7,500 restricted stock units and a share option for 10,000 ordinary shares at an exercise price of $2.26 per share, expiring July 29, 2036. Both the RSUs and the option vest 25% on October 1, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued service. After these awards, Gilead directly holds 18,907 ordinary shares and options for 10,000 shares.
Compugen Ltd director Sanford S. Zweifach received equity-based compensation on July 29, 2026. He was granted 7,500 restricted stock units and a share option for 10,000 ordinary shares at an exercise price of $2.26. Both awards vest 25% on October 1, 2027 and the remainder in 12 equal quarterly installments, subject to continued service. Following these awards he directly holds 20,180 ordinary shares and 10,000 options.
Compugen Chief Medical Officer Michelle Mahler received equity awards on July 29, 2026, consisting of 13,500 restricted stock units and a stock option for 18,000 ordinary shares at an exercise price of $2.26 per share. Both awards vest 25% on September 30, 2027, with the remainder in 12 equal quarterly installments, subject to her continued service. Following the RSU grant, she directly holds 36,625 ordinary shares.
Compugen Ltd senior vice president of business development Zurit Levine exercised options to acquire 1,875 Ordinary Shares at $0.8292 per share and, on the same date, sold 1,875 Ordinary Shares at $2.50 per share in an open-market transaction. The trades were made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, Levine directly holds 29,375 Ordinary Shares and 3,750 share options with a $0.8292 exercise price expiring on November 9, 2032.
Compugen Ltd SVP of Business Development Zurit Levine exercised options and sold shares in a pre-planned transaction. On April 24, 2026, she exercised 2,000 share options at $1.15 per share and sold 2,000 ordinary shares at $3.20 per share in an open-market sale pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025. Following these transactions, she directly held 29,375 ordinary shares.
Compugen Ltd President and CEO Ophir Eran reported an exercise-and-sale transaction in the company’s Ordinary Shares. On April 24, 2026, he exercised options to acquire 5,000 shares at an exercise price of $0.8292 per share and sold 5,000 shares in open-market trades at a weighted average price of $3.2001 per share. Following these transactions, he directly holds 11,375 Ordinary Shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025.
Compugen Ltd President and CEO Ophir Eran exercised options to acquire 5,000 ordinary shares at an exercise price of $0.8292 per share, then sold 5,000 shares in an open-market transaction at a weighted average price of $2.9042.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025. Following these transactions, Eran directly owns 11,375 ordinary shares. The exercised option was from a grant that vested over time through quarterly installments.
Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold a small portion of shares. On April 14, 2026, she exercised options for 2,000 Ordinary Shares at $1.15 per share and sold 2,000 Ordinary Shares at $2.80 per share in an open-market transaction.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, she directly holds 29,375 Ordinary Shares, reflecting a relatively modest reduction in her equity position.
Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold shares in a planned transaction. On April 10, 2026, she exercised options for 3,125 Ordinary Shares at exercise prices of $0.8292 and $1.15, then sold 3,125 Ordinary Shares at a weighted average price of $2.564 pursuant to a Rule 10b5-1 trading plan. Following these transactions, she directly holds 29,375 Ordinary Shares.
Compugen Ltd. senior vice president Zurit Levine exercised share options and sold shares in a planned transaction. On April 10, 2026, she exercised options for a total of 3,125 Ordinary Shares at strike prices of $0.8292 and $1.15 per share, then sold 3,125 Ordinary Shares at a weighted average price of $2.564 per share under a Rule 10b5-1 trading plan. Following these transactions, she holds 29,375 Ordinary Shares directly and retains share option positions totaling 5,625 and 56,000 options, respectively.
Compugen Ltd senior vice president of business development Zurit Levine reported a series of option exercises and share sales. On April 7–8, 2026, Levine exercised share options for a total of 7,875 Ordinary Shares at exercise prices of $0.8292 and $1.15, then sold 7,875 Ordinary Shares in open-market transactions at prices of $2.30 and $2.42. Following these transactions, Levine directly holds 29,375 Ordinary Shares. The filing notes these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025.
Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold shares in a pre-planned transaction. On this Form 4, Levine exercised options to acquire 3,500 Ordinary Shares at exercise prices of $0.8292 and $1.15 per share, then sold 3,500 Ordinary Shares at $2.20 per share.
The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025, indicating they were pre-arranged. After these trades, Levine directly holds 29,375 Ordinary Shares.
COMPUGEN LTD President and CEO Ophir Eran exercised stock options and sold shares in a planned transaction. On this Form 4, he exercised options to acquire 5,625 Ordinary Shares at an exercise price of $0.8292 per share, converting a derivative position into common stock. On the same date, he sold 5,625 Ordinary Shares at a weighted average price of $2.2067 per share in open-market transactions made under a Rule 10b5-1 trading plan adopted on December 26, 2025. Following these transactions, he directly holds 11,375 Ordinary Shares and 24,375 Share Options.
COMPUGEN LTD senior vice president of business development Zurit Levine exercised stock options and sold shares in a planned transaction. She exercised options for 11,875 ordinary shares at an exercise price of $0.8292 per share, then sold 11,875 ordinary shares at a weighted average price of $2.0368 per share.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating it was scheduled in advance rather than timed discretionarily. Following these transactions, Levine holds 29,375 ordinary shares directly.